ReviewCurrent gastroenterology reports2010
Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
Review in Current gastroenterology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.Clinical pharmacology and therapeutics · 2013Trial
- The Investigation of Therapeutic Implications of Mast Cell Stabilizer Cromolyn Sodium on Cholestasis and Cholestatic Pruritus in Experimental Cholestasis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Bile acid metabolism and signaling in liver disease and therapy.Liver research (Beijing, China) · 2017Article
- Recent advances in the management of pruritus in chronic liver diseases.World journal of gastroenterology · 2017Review
- Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats.World journal of gastroenterology · 2015Article
- Management of pruritus in chronic liver disease.Dermatology research and practice · 2015Review
- Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.Journal of hepatology · 2013Article
- Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction.PloS one · 2013Article
- Novel insight into mechanisms of cholestatic liver injury.World journal of gastroenterology · 2012Review
- [Treatment of autoimmune liver diseases. Autoimmune hepatitis and primary sclerosing cholangitis].Der Internist · 2011Article
- Role of nuclear receptor SHP in metabolism and cancer.Biochimica et biophysica acta · 2011Review
- Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.Hepatology (Baltimore, Md.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical, histologic, and survival benefits. However, a need for different or adjuvant therapies remains for specific subsets of PBC patients, including those who do not respond to UDCA and those who have advanced histologic disease at presentation. Similarly, beneficial therapies for disease-related symptoms that do not typically respond to UDCA (eg, fatigue and pruritus) are still needed. In contrast to PBC, no medical therapy of proven benefit has been identified for patients with PSC. In PBC and PSC, adequate management of complications of chronic cholestasis is important. For both diseases, liver transplantation is the only curative option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.